echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Ther Adv Med Oncol: Reveal the 20-year treatment and clinical prognosis of patients with HER2+ advanced breast cancer (PANHER study)

    Ther Adv Med Oncol: Reveal the 20-year treatment and clinical prognosis of patients with HER2+ advanced breast cancer (PANHER study)

    • Last Update: 2022-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, scholars from Italy published observational PANHER research results in Therapeutic Advances in Medical Oncology, mainly to evaluate the efficacy and prognosis of anti-HER2 therapy in patients with HER2+ advanced breast cancer (BC)
    .

    Breast cancer

    The PANHER study included 1328 HER2-positive advanced BC patients who received anti-HER2 therapy from June 2000 to July 2020
    .
    The efficacy endpoints are progression-free survival (PFS) and overall survival (OS)

    .
    Among the 1328 patients, the median age at initial
    diagnosis was 52 years (range 24-88), the Eastern Cooperative Oncology Group (ECOG) median PS status was 1 (range 0-3), and 564 (42.
    5%) patients were Before menopause, 764 patients (57.
    5%) were postmenopausal

    .
    In total, 680 (51.
    2%) HER2-positive tumors also expressed hormone receptor-positive, that is, triple-positive (TP), and 202 (15.
    2%) tumors only expressed ER or PgR

    .
    Neither hormone receptor was expressed in 397 cases (29.
    9%)

    .

    diagnosis

    First-line treatment: 358 patients (26.
    9%) with trastuzumab + chemotherapy, 749 patients (56.
    4%) with Pertuzumab/trastuzumab/taxane, and 37 patients (2.
    8%) with T-DM1 Among the patients, 41 patients (3.
    4%) of lapatinib/capecitabine, and 143 patients (10.
    7%) of other treatments, such as endocrine therapy + trastuzumab

    .
    Second-line treatment: 335 cases (41.
    5%) for T-DM1, 175 cases (21.
    7%) for lapatinib/capecitabine, 152 cases (18.
    8%) for trastuzumab + chemotherapy, trastuzumab Anti-+endocrine therapy was 37 cases (4.
    6%), and other treatments were 108 cases (13.
    4%)

    .
    Third-line treatment: Lapatinib/Capecitabine is the most commonly used dosing regimen (144, 29.
    3%), and T-DM1 has 102 (20.
    5%) patients

    .

    The median follow-up time for the overall population was 52 months (95% CI, 48-56)
    .
    In the first-line treatment, the 2-year PFS rate of 749 patients who received Pertuzumab/trastuzumab/taxane was 50.
    5%, and the median PFS was 25 months (95% CI, 20.
    8 29.
    2)

    .
    In contrast, in the 412 patients receiving trastuzumab-based first-line therapy, the 2-year PFS rate was 30.
    5%, and the median PFS was 14 months (95% CI, 12.
    2-15.
    6, p = 0.
    0001)

    .
    In addition, the 2-year PFS rate of Pertuzumab as the basic treatment regimen was 50.
    5%, while the 2-year PFS rate of trastuzumab + chemotherapy was 34.
    6%.
    The median PFS of the two groups was 25 (95% CI , 21–29) and 17 (95% CI, 15–19) months (p <0.
    0001)

    .

    In the first-line treatment, the 2-year PFS rate of 749 patients who received Pertuzumab/trastuzumab/taxane was 50.
    5%, and the median PFS was 25 months (95% CI, 20.
    8 29.
    2)

    .
    In contrast, in the 412 patients receiving trastuzumab-based first-line therapy, the 2-year PFS rate was 30.
    5%, and the median PFS was 14 months (95% CI, 12.
    2-15.
    6, p = 0.
    0001)

    .
    In addition, the 2-year PFS rate of Pertuzumab as the basic treatment regimen was 50.
    5%, while the 2-year PFS rate of trastuzumab + chemotherapy was 34.
    6%.
    The median PFS of the two groups was 25 (95% CI , 21–29) and 17 (95% CI, 15–19) months (p <0.
    0001)

    .
    In the first-line treatment, the 2-year PFS rate of 749 patients who received Pertuzumab/trastuzumab/taxane was 50.
    5%, and the median PFS was 25 months (95% CI, 20.
    8 29.
    2)

    .
    In contrast, in the 412 patients receiving trastuzumab-based first-line therapy, the 2-year PFS rate was 30.
    5%, and the median PFS was 14 months (95% CI, 12.
    2-15.
    6, p = 0.
    0001)

    .
    In addition, the 2-year PFS rate of Pertuzumab as the basic treatment regimen was 50.
    5%, while the 2-year PFS rate of trastuzumab + chemotherapy was 34.
    6%.
    The median PFS of the two groups was 25 (95% CI , 21–29) and 17 (95% CI, 15–19) months (p <0.
    0001)

    .

    807 patients received second-line treatment, the 2-year PFS rate was 20%, and the median PFS was 8 months (95% CI, 7.
    1-8.
    7)

    .
    The 2-year PFS rate of patients treated with T-DM1 was 24.
    4%, and the median PFS was 8 months, while the 2-year PFS rate of patients receiving other second-line treatments was 17%, and the median PFS was 9 months

    .
    No differences were observed
    statistical significance (= the p-0.
    22)

    .
    In the second-line treatment of TDM-1, the 2-year PFS rate of patients treated with Patolizumab was 22.
    6%, the median PFS was 7 months (95% CI, 5.
    1-8.
    9), and Patolizumab was not used before The 2-year PFS rate of treated patients was 30.
    3%, and the median PFS was less than 12 months (95% CI, 5.
    8–18.
    2) (p = 0.
    01)

    .

    807 patients received second-line treatment, the 2-year PFS rate was 20%, and the median PFS was 8 months (95% CI, 7.
    1-8.
    7)

    .
    The 2-year PFS rate of patients treated with T-DM1 was 24.
    4%, and the median PFS was 8 months, while the 2-year PFS rate of patients receiving other second-line treatments was 17%, and the median PFS was 9 months

    .
    No differences were observed
    statistical significance (= the p-0.
    22)

    .
    In the second-line treatment of TDM-1, the 2-year PFS rate of patients treated with Patolizumab was 22.
    6%, the median PFS was 7 months (95% CI, 5.
    1-8.
    9), and Patolizumab was not used before The 2-year PFS rate of treated patients was 30.
    3%, and the median PFS was less than 12 months (95% CI, 5.
    8–18.
    2) (p = 0.
    01)

    .
    807 patients received second-line treatment, the 2-year PFS rate was 20%, and the median PFS was 8 months (95% CI, 7.
    1-8.
    7)

    .
    The 2-year PFS rate of patients treated with T-DM1 was 24.
    4%, and the median PFS was 8 months, while the 2-year PFS rate of patients receiving other second-line treatments was 17%, and the median PFS was 9 months

    .
    No differences were observed
    statistical significance (= the p-0.
    22)

    .
    In the second-line treatment of TDM-1, the 2-year PFS rate of patients treated with Patolizumab was 22.
    6%, the median PFS was 7 months (95% CI, 5.
    1-8.
    9), and Patolizumab was not used before The 2-year PFS rate of treated patients was 30.
    3%, and the median PFS was less than 12 months (95% CI, 5.
    8–18.
    2) (p = 0.
    01)

    .
    statistics

    The median PFS of first-line patolizumab was 7 months (95% CI, 2.
    1-11.
    9) and 7 months (95%) for second-line lapatinib/capecitabine or TDM-1 treatment, respectively CI 5.
    1–8.
    9) (p = 0.
    80)

    .
    For patients who have not previously been treated with patolizumab, the median PFS of second-line lapatinib/capecitabine or TDM-1 treatment was 8 months (95% CI, 6.
    4–9.
    6) and 12 months, respectively (95% CI, 5.
    8–18.
    2) (p = 0.
    004)

    .

    The median PFS of first-line patolizumab was 7 months (95% CI, 2.
    1-11.
    9) and 7 months (95%) for second-line lapatinib/capecitabine or TDM-1 treatment, respectively CI 5.
    1–8.
    9) (p = 0.
    80)

    .
    For patients who have not previously been treated with patolizumab, the median PFS of second-line lapatinib/capecitabine or TDM-1 treatment was 8 months (95% CI, 6.
    4–9.
    6) and 12 months, respectively (95% CI, 5.
    8–18.
    2) (p = 0.
    004)

    .
    The median PFS of first-line patolizumab was 7 months (95% CI, 2.
    1-11.
    9) and 7 months (95%) for second-line lapatinib/capecitabine or TDM-1 treatment, respectively CI 5.
    1–8.
    9) (p = 0.
    80)

    .
    For patients who have not previously been treated with patolizumab, the median PFS of second-line lapatinib/capecitabine or TDM-1 treatment was 8 months (95% CI, 6.
    4–9.
    6) and 12 months, respectively (95% CI, 5.
    8–18.
    2) (p = 0.
    004)

    .

    The 2-year PFS rate of the third-line treatment was 8.
    5%, and the median PFS was 7 months (95% CI, 6.
    3-7.
    7).
    There was no significant difference between different treatment regimens

    .

    In the overall population, the median OS was 60 months (95% CI, 55 65), the 3-year OS rate was 68.
    4%, and the 5-year OS rate was 49.
    7%

    .
    In 1328 patients, after diagnosis of metastatic disease, the 3-year OS rate, 5-year OS rate and median OS rate of Pertuzumab/Trastuzumab/Taxane treatment after diagnosis of metastatic disease were 71.
    4% and 56.
    4%, respectively , And 70 months (95% CI, 60-80); while those receiving treatment without patolizumab were 65.
    4%, 45.
    5%, and 55 months (95% CI, 49-61) (p = 0.
    004)

    .

    In the overall population, the median OS was 60 months (95% CI, 55 65), the 3-year OS rate was 68.
    4%, and the 5-year OS rate was 49.
    7%

    .
    In 1328 patients, after diagnosis of metastatic disease, the 3-year OS rate, 5-year OS rate and median OS rate of Pertuzumab/Trastuzumab/Taxane treatment after diagnosis of metastatic disease were 71.
    4% and 56.
    4%, respectively , And 70 months (95% CI, 60-80); while those receiving treatment without patolizumab were 65.
    4%, 45.
    5%, and 55 months (95% CI, 49-61) (p = 0.
    004)

    .
    In the overall population, the median OS was 60 months (95% CI, 55 65), the 3-year OS rate was 68.
    4%, and the 5-year OS rate was 49.
    7%

    .
    In 1328 patients, after diagnosis of metastatic disease, the 3-year OS rate, 5-year OS rate and median OS rate of Pertuzumab/Trastuzumab/Taxane treatment after diagnosis of metastatic disease were 71.
    4% and 56.
    4%, respectively , And 70 months (95% CI, 60-80); while those receiving treatment without patolizumab were 65.
    4%, 45.
    5%, and 55 months (95% CI, 49-61) (p = 0.
    004)

    .

    Overall, among the 807 patients who received second-line treatment, the median OS from the second-line was 28 months (95% CI, 24.
    8 31.
    1), the 3-year OS rate was 41.
    0%, and the 5-year OS rate was 24.
    8%

    .
    Among the 749 patients who received first-line pembrolizumab treatment, those who received second-line T-DM1 treatment (N: 259) had a 3-year OS rate of 63.
    6% and a 5-year OS rate of 39.
    5%, from the diagnosis to metastatic disease The initial median OS was 48 months (95% CI, 42 54)

    .
    In the second-line patients receiving lapatinib/capecitabine, the 3-year OS rate was 51.
    8%, the 5-year OS rate was 32.
    2%, and the median OS was 41 months (95% CI, 28 54) (p = 0.
    45) )

    .

    Overall, among the 807 patients who received second-line treatment, the median OS from the second-line was 28 months (95% CI, 24.
    8 31.
    1), the 3-year OS rate was 41.
    0%, and the 5-year OS rate was 24.
    8%

    .
    Among the 749 patients who received first-line pembrolizumab treatment, those who received second-line T-DM1 treatment (N: 259) had a 3-year OS rate of 63.
    6% and a 5-year OS rate of 39.
    5%, from the diagnosis to metastatic disease The initial median OS was 48 months (95% CI, 42 54)

    .
    In the second-line patients receiving lapatinib/capecitabine, the 3-year OS rate was 51.
    8%, the 5-year OS rate was 32.
    2%, and the median OS was 41 months (95% CI, 28 54) (p = 0.
    45) )

    .
    Overall, among the 807 patients who received second-line treatment, the median OS from the second-line was 28 months (95% CI, 24.
    8 31.
    1), the 3-year OS rate was 41.
    0%, and the 5-year OS rate was 24.
    8%

    .
    Among the 749 patients who received first-line pembrolizumab treatment, those who received second-line T-DM1 treatment (N: 259) had a 3-year OS rate of 63.
    6% and a 5-year OS rate of 39.
    5%, from the diagnosis to metastatic disease The initial median OS was 48 months (95% CI, 42 54)

    .
    In the second-line patients receiving lapatinib/capecitabine, the 3-year OS rate was 51.
    8%, the 5-year OS rate was 32.
    2%, and the median OS was 41 months (95% CI, 28 54) (p = 0.
    45) )

    .

    When OS was diagnosed with metastatic disease, TDM-1 was the second-line treatment.
    The 3-year OS rate of patients who had not been treated with Pertuzumab was 78%, and the 5-year OS rate was 55.
    4%.
    From the diagnosis of metastatic disease The initial median OS was 72 months (95% CI, 44-100), which significantly improved the prognosis of patients compared with previous treatment with patozumab (p = 0.
    003)

    .

    When OS was diagnosed with metastatic disease, TDM-1 was the second-line treatment.
    The 3-year OS rate of patients who had not been treated with Pertuzumab was 78%, and the 5-year OS rate was 55.
    4%.
    From the diagnosis of metastatic disease The initial median OS was 72 months (95% CI, 44-100), which significantly improved the prognosis of patients compared with previous treatment with patozumab (p = 0.
    003)

    .
    When OS was diagnosed with metastatic disease, TDM-1 was the second-line treatment.
    The 3-year OS rate of patients who had not been treated with Pertuzumab was 78%, and the 5-year OS rate was 55.
    4%.
    From the diagnosis of metastatic disease The initial median OS was 72 months (95% CI, 44-100), which significantly improved the prognosis of patients compared with previous treatment with patozumab (p = 0.
    003)

    .

    When OS starts from second-line treatment, TDM-1 is second-line treatment.
    The 3-year OS rate of patients who have not been treated with Pertuzumab in the past was 58.
    9%, and the 5-year OS rate was 38.
    5%, the median from the diagnosis of metastatic disease OS was 45 months (95% CI, 36–54); the 3-year OS rate of patients treated with Pertuzumab was 32.
    2%, and the 5-year OS rate was 24.
    4%, the median from the diagnosis of metastatic disease OS was 24 months (95% CI, 19-29) (p = 0.
    002)

    .

    When OS starts from second-line treatment, TDM-1 is second-line treatment.
    The 3-year OS rate of patients who have not been treated with Pertuzumab in the past was 58.
    9%, and the 5-year OS rate was 38.
    5%, the median from the diagnosis of metastatic disease OS was 45 months (95% CI, 36–54); the 3-year OS rate of patients treated with Pertuzumab was 32.
    2%, and the 5-year OS rate was 24.
    4%, the median from the diagnosis of metastatic disease OS was 24 months (95% CI, 19-29) (p = 0.
    002)

    .
    When OS starts from second-line treatment, TDM-1 is second-line treatment.
    The 3-year OS rate of patients who have not been treated with Pertuzumab in the past was 58.
    9%, and the 5-year OS rate was 38.
    5%, the median from the diagnosis of metastatic disease OS was 45 months (95% CI, 36–54); the 3-year OS rate of patients treated with Pertuzumab was 32.
    2%, and the 5-year OS rate was 24.
    4%, the median from the diagnosis of metastatic disease OS was 24 months (95% CI, 19-29) (p = 0.
    002)

    .

    In summary, studies have shown that compared with patients who were not treated with first-line patolizumab, the efficacy of second-line use of TDM-1 after treatment with patolizumab in the past has been reduced
    .

    Studies have shown that, compared with patients who were not treated with first-line patolizumab, the efficacy of second-line TDM-1 after the previous treatment with patolizumab was reduced
    .
    Studies have shown that, compared with patients who were not treated with first-line patolizumab, the efficacy of second-line TDM-1 after the previous treatment with patolizumab is reduced
    .

    Original source:

    Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti,et al.
    PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
    Ther Adv Med Oncol.
    2021, Vol .
    13: 1 -18.
    DOI: 10.
    1177/17588359211059873.



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.